Alopecia Areata and Ritlecitinib: Unraveling Response Trajectories

The study investigates the long-term response patterns to ritlecitinib, a JAK3/TEC family kinase inhibitor, in treating alopecia areata (AA). It analyzes data from the ALLEGRO-2b/3 and ALLEGRO-LT trials, categorizing patients into six responder groups based on the Severity of Alopecia Tool (SALT) score. The study found that 45.5% of patients achieved a SALT score ≤ 20, with 46.0% attaining complete hair regrowth, and 93.1% of responders maintained their response over 24 months. The analysis highlights that less severe and shorter-duration AA cases respond better, with female patients more likely to experience favorable outcomes. The study suggests that initiating treatment before severe AA onset may yield better results and calls for further research to optimize management, including exploring combination therapies and alternative JAK inhibitors.